Literature DB >> 9525899

Differences in activity between alpha and beta type I interferons explored by mutational analysis.

L Runkel1, L Pfeffer, M Lewerenz, D Monneron, C H Yang, A Murti, S Pellegrini, S Goelz, G Uzé, K Mogensen.   

Abstract

Type I interferon (IFN) subtypes alpha and beta share a common multicomponent, cell surface receptor and elicit a similar range of biological responses, including antiviral, antiproliferative, and immunomodulatory activities. However, alpha and beta IFNs exhibit key differences in several biological properties. For example, IFN-beta, but not IFN-alpha, induces the association of tyrosine-phosphorylated receptor components ifnar1 and ifnar2, and has activity in cells lacking the IFN receptor-associated, Janus kinase tyk2. To define the structural basis for these functional differences we produced human IFN-beta with point mutations and compared them to wild-type IFN-beta in assays that distinguish alpha and beta IFN subtypes. IFN-beta mutants with charged residues (N86K, N86E, or Y92D) introduced at two positions in the C helix lost the ability to induce the association of tyrosine-phosphorylated receptor chains and had reduced activity on tyk2-deficient cells. The combination of negatively charged residues N86E and Y92D (homologous with IFN-alpha8) increased the cross-species activity of the mutant IFN-betas on bovine cells to a level comparable to that of human IFN-alphas. In contrast, point mutations in the AB loop and D helix had no significant effect on these subtype-specific activities. A subset of these latter mutations did, however, reduce activity in a manner analogous to IFN-alpha mutations. The effects of these mutations on IFN-beta activity are discussed in the context of a family of related ligands acting through a common receptor and signaling pathway.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9525899     DOI: 10.1074/jbc.273.14.8003

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

1.  Impaired antiviral response and alpha/beta interferon induction in mice lacking beta interferon.

Authors:  R Deonarain; A Alcamí; M Alexiou; M J Dallman; D R Gewert; A C Porter
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

Review 2.  Interferon-zeta/limitin: novel type I interferon that displays a narrow range of biological activity.

Authors:  Kenji Oritani; Yoshiaki Tomiyama
Journal:  Int J Hematol       Date:  2004-11       Impact factor: 2.490

3.  Determination of the human type I interferon receptor binding site on human interferon-alpha2 by cross saturation and an NMR-based model of the complex.

Authors:  Sabine R Quadt-Akabayov; Jordan H Chill; Rina Levy; Naama Kessler; Jacob Anglister
Journal:  Protein Sci       Date:  2006-09-25       Impact factor: 6.725

4.  A compartmentalized type I interferon response in the gut during chronic HIV-1 infection is associated with immunopathogenesis.

Authors:  Stephanie M Dillon; Kejun Guo; Gregory L Austin; Sara Gianella; Phillip A Engen; Ece A Mutlu; John Losurdo; Garth Swanson; Prachi Chakradeo; Ali Keshavarzian; Alan L Landay; Mario L Santiago; Cara C Wilson
Journal:  AIDS       Date:  2018-07-31       Impact factor: 4.177

5.  The role of TRAF2 binding to the type I interferon receptor in alternative NF kappaB activation and antiviral response.

Authors:  Chuan He Yang; Aruna Murti; Susan R Pfeffer; Meiyun Fan; Ziyun Du; Lawrence M Pfeffer
Journal:  J Biol Chem       Date:  2008-03-24       Impact factor: 5.157

6.  Inquiring into the differential action of interferons (IFNs): an IFN-alpha2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta.

Authors:  Diego A Jaitin; Laila C Roisman; Eva Jaks; Martynas Gavutis; Jacob Piehler; Jose Van der Heyden; Gilles Uze; Gideon Schreiber
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

7.  Comparable potency of IFNalpha2 and IFNbeta on immediate JAK/STAT activation but differential down-regulation of IFNAR2.

Authors:  Zrinka Marijanovic; Josiane Ragimbeau; José van der Heyden; Gilles Uzé; Sandra Pellegrini
Journal:  Biochem J       Date:  2007-10-01       Impact factor: 3.857

8.  Selective Blockade of Interferon-α and -β Reveals Their Non-Redundant Functions in a Mouse Model of West Nile Virus Infection.

Authors:  Kathleen C F Sheehan; Helen M Lazear; Michael S Diamond; Robert D Schreiber
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

9.  Glycoengineering of interferon-β 1a improves its biophysical and pharmacokinetic properties.

Authors:  Kyoung Song; In-Soo Yoon; Nam Ah Kim; Dong-Hwan Kim; Jongmin Lee; Hee Jung Lee; Saehyung Lee; Sunghyun Choi; Min-Koo Choi; Ha Hyung Kim; Seong Hoon Jeong; Woo Sung Son; Dae-Duk Kim; Young Kee Shin
Journal:  PLoS One       Date:  2014-05-23       Impact factor: 3.240

Review 10.  The Role of Latently Infected B Cells in CNS Autoimmunity.

Authors:  Ana Citlali Márquez; Marc Steven Horwitz
Journal:  Front Immunol       Date:  2015-10-28       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.